Repeatability of nerve fiber layer thickness measurements in patients with glaucoma and without glaucoma using spectral-domain and time-domain OCT

Marc Töteberg-Harms, Veit Sturm, Pascal B Knecht, Jens Funk, Marcel N Menke, Marc Töteberg-Harms, Veit Sturm, Pascal B Knecht, Jens Funk, Marcel N Menke

Abstract

Background: The aim of this work is to assess the repeatability of spectral-domain-OCT (SD-OCT) retinal nerve fiber layer thickness (RNFL) thickness measurements in a non-glaucoma group and patients with glaucoma and to compare these results to conventional time-domain-OCT (TD-OCT).

Methods: In a prospective, comparative, observational case-control study, 50 eyes of 25 non-glaucoma and 22 eyes of 11 patients with primary open angle glaucoma (POAG) were included. SD-OCT and TD-OCT circle scans were centered on the optic disc. In each eye, OCT scans were performed three times by two independent observers. RNFL thickness was measured in four quadrants around the optic disc. In addition, the overall mean RNFL thickness was assessed. Intraclass correlation coefficients (ICC) and coefficients of variation (COV) were calculated. Inter-observer and inter-OCT repeatability was visualized by using Bland-Altman analysis.

Results: Intra-observer repeatability for TD- OCT was good with an ICC(mean RNFL thickness) of 0.939 in non-glaucomas and 0.980 in glaucomatous eyes. For SD-OCT, intra-observer repeatability was higher with an ICC of 0.989 for non-glaucomas and 0.997 for glaucomatous eyes. COVs for TD-OCT ranged from 2.9-7.7% in non-glaucomas and from 6.0-13.3% in glaucoma patients. COVs for SD-OCT ranged from 0.3-1% in non-glaucomas and from 0.9-2.3% in glaucomatous eyes. COVs were influenced by various factors. In the glaucoma group, COVs were significantly higher (p < 0.001) compared to the non-glaucoma group. COVs increased by a mean of 5.1% when TD-OCT was used instead of SD-OCT (p < 0.001).

Conclusions: SD-OCT RNFL thickness measurements in healthy volunteers and glaucoma patients showed good intra- and inter-observer repeatability. Especially in glaucomatous eyes, repeatability of SD-OCT was superior to TD-OCT.

Trial registration: ClinicalTrials.gov NCT01273285.

References

    1. J Glaucoma. 2011 Jan;20(1):15-20
    1. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4104-9
    1. Ophthalmology. 2003 Jan;110(1):190-5
    1. Opt Express. 2003 Sep 8;11(18):2183-9
    1. Invest Ophthalmol Vis Sci. 2010 Feb;51(2):896-902
    1. Ophthalmology. 2008 Apr;115(4):661-666.e4
    1. Jpn J Ophthalmol. 2010 Jan;54(1):43-7
    1. J Glaucoma. 2010 Sep;19(7):475-82
    1. Ophthalmology. 2000 Dec;107(12):2278-82
    1. Invest Ophthalmol Vis Sci. 2004 Jun;45(6):1716-24
    1. Invest Ophthalmol Vis Sci. 2010 Jan;51(1):217-22
    1. Ophthalmology. 2009 Jul;116(7):1257-63, 1263.e1-2
    1. Br J Ophthalmol. 2009 Aug;93(8):1057-63
    1. Br J Ophthalmol. 2009 Jun;93(6):775-81
    1. Invest Ophthalmol Vis Sci. 2007 Jul;48(7):3154-60
    1. Lancet. 1986 Feb 8;1(8476):307-10
    1. Can J Ophthalmol. 2009 Oct;44(5):562-6
    1. Semin Ophthalmol. 2000 Dec;15(4):206-20
    1. Ophthalmologe. 2005 Dec;102(12):1175-8, 1180
    1. Ophthalmology. 1996 Nov;103(11):1889-98
    1. Ophthalmology. 2005 Oct;112(10):1734-46
    1. J Glaucoma. 2000 Feb;9(1):56-62
    1. Ophthalmology. 2009 Dec;116(12):2294-9
    1. Stat Methods Med Res. 1999 Jun;8(2):135-60
    1. Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1280-5
    1. Trans Am Ophthalmol Soc. 2008;106:426-58
    1. Am J Ophthalmol. 2009 Jun;147(6):1067-74, 1074.e1
    1. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2440-3
    1. Curr Opin Ophthalmol. 1995 Apr;6(2):89-95
    1. Ophthalmology. 2009 Jul;116(7):1271-7
    1. Br J Ophthalmol. 2001 Jun;85(6):673-7
    1. Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5386-91
    1. Opt Express. 2004 May 31;12(11):2404-22
    1. Ophthalmology. 2009 Jul;116(7):1264-70, 1270.e1
    1. Int Ophthalmol Clin. 2008 Fall;48(4):29-45
    1. Arch Ophthalmol. 2009 Dec;127(12):1603-9

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi